Page 4 - மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் Today - Breaking & Trending Today

Covaxin Phase 2-3 Clinical Trials for Age Group 2-18 Begins on June

Covaxin Phase 2-3 Clinical Trials for Age Group 2-18 Begins on June
Bharat Biotech s Covaxin will begin Phase 2 and 3 clinical trials in the age group of 2 to 18 years in June, according to sources at the Hyderabad-based vaccine manufacturer.
| 24 May 2021 1:11 PM GMT
Bharat Biotech s Covaxin will begin Phase 2 and 3 clinical trials in the age group of 2 to 18 years in June, according to sources at the Hyderabad-based vaccine manufacturer.
Covaxin is being used on adults in India s ongoing Covid-19 vaccination drive, which was created by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR). Bharat Biotech was granted permission to conduct a Phase 2/3 clinical trial of Covaxin in children aged 2 to 18 years old earlier this month. ....

Andhra Pradesh , Indian Council Of Medical Research , Meditrina Institute Of Medical Sciences , Expert Committee , Bharat Biotech , Indian Council , Medical Research , Meditrina Institute , Medical Sciences , Indian Drugs Controller General , Subject Expert Committee , Couple Ties Nuptial Nod Mid Air , Covaxin For 2 18 Yrs Old , Ovaxin Vaccination Latest News , Covaxin Clinical Trials , Covaxin Clinical Trials Children , Clinical Trials , Covaxin News , Covaxin Vaccine , Covid Vaccine India , Covaxin Doses Children , ஆந்திரா பிரதேஷ் , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் , நிபுணர் குழு , பாரத் பயோடெக் ,

Covaxin Phase 2-3 clinical trials for 2-18 age group to begin in June, youngest participant 2-year-old

Covaxin Phase 2-3 clinical trials for 2-18 age group to begin in June, youngest participant 2-year-old
The Phase 2-3 clinical trials of Covaxin, which has been approved by the DCGI for the age group of 2 to 18 years, will begin in June, as per reliable sources.
advertisement
UPDATED: May 24, 2021 13:49 IST
In the trials, Covaxin will be given by intramuscular route in two doses at day 0 and day 28. (PTI photo for representation)
The Phase 2 and 3 clinical trials of Bharat Biotech’s Covaxin in the age group of 2 to 18 years will begin in June, sources in the Hyderabad-based vaccine maker have said.
Sources at Bharat Biotech told India Today that the Phase 2/3 trails for children will begin in June. Dosing will begin in June and end by mid-July. The youngest child recruited for the clinical study is a two-year-old, Bharat Biotech sources added. ....

Andhra Pradesh , Indian Council Of Medical Research , Meditrina Institute Of Medical Sciences , Expert Committee , Bharat Biotech , Indian Council , Medical Research , India Today , Meditrina Institute , Medical Sciences , Drugs Controller General , Subject Expert Committee , Covaxin For Kids , Vaccine For Kids , Hen Will Kids Get Vaccine , ஆந்திரா பிரதேஷ் , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் , நிபுணர் குழு , பாரத் பயோடெக் , இந்தியன் சபை , மருத்துவ ஆராய்ச்சி , இந்தியா இன்று , மேதிற்றின நிறுவனம் , மருத்துவ அறிவியல் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் ,

Covaxin production ramped to 1 billion doses per year: Bharat Biotech

Covaxin production ramped to 1 billion doses per year: Bharat Biotech
The additional doses would be produced at its wholly-owned subsidiary Chiron Behring Vaccines situated in Ankleshwar, Gujarat and the product availability will commence from Q4 2021
BusinessToday.In | May 20, 2021 | Updated 22:35 IST
Homegrown biotechnology company Bharat Biotech, on Thursday, announced expansion of Covaxin production capacity by 200 million doses, taking its total capacity to around 1 billion doses per annum.
Bharat Biotech, in a statement, said the company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. ....

Vero Cell Platform Technology , Meditrina Institute Of Medical Sciences , Bharat Biotech , Inactivated Vero Cell Platform Technology , Chiron Behring Vaccines , Drugs Controller General , Meditrina Institute , Medical Sciences , Chiron Behring Vaccines , Vk Paul , Niti Aayog , Drugs Controller General Of India , Meditrina Institute Of Medical Sciences , மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் , பாரத் பயோடெக் , சிரோன் பெஹ்ரிங் தடுப்பு மருந்துகள் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , மேதிற்றின நிறுவனம் , மருத்துவ அறிவியல் ,

Do Kids Need Covid Vaccines, What Are The Side Effects And Precautions, Know From Expert

Do Kids Need Covid Vaccines, What Are The Side Effects And Precautions, Know From Expert
Outlook got in touch with Dr. Prabhat Maheshwari, Chief- Neonatal & Paediatric Critical Care, Artemis Hospitals Gurgaon to answer all your questions:
Dr. Prabhat Maheshwari
17 May 2021, Last Updated at 7:30 am
File photo
Dr. Prabhat Maheshwari
2021-05-17T07:25:02+05:30
Do Kids Need Covid Vaccines, What Are The Side Effects And Precautions, Know From Expert
outlookindia.com
2021-05-17T07:30:29+05:30
Also read
With Bharat Biotech’s inactivated virus-based Covid-19 vaccine Covaxin now set for phase 2 and 3 clinical trials on children in the 2-12 years age group, the stage is set for a pediatric range to hit the market. Experts believe this is a critical step to ensure a break in transmission. ....

Prabhat Maheshwari , Zydus Cadila Zyco , Krishna Ella , Indian Council Of Medical Research , Meditrina Institute Of Medical Sciences , With Bharat Biotech , Zydus Cadila , Biotech Chairman , Managing Director Krishna Ella , Paediatric Critical Care , Artemis Hospitals Gurgaon , Bharat Biotech , Indian Council , Medical Research , Controller General , Meditrina Institute , Medical Sciences , பிரபத் மகேஸ்வரி , கிருஷ்ணா எல்லா , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் , உடன் பாரத் பயோடெக் , ஜய்துச் காடிலா , பயோடெக் தலைவர் , நிர்வகித்தல் இயக்குனர் கிருஷ்ணா எல்லா , குழந்தை முக்கியமான பராமரிப்பு ,

Covid Explained: How Phase 2 And 3 Trials For Covaxin On Kids Will Be Conducted?

Covid Explained: How Phase 2 And 3 Trials For Covaxin On Kids Will Be Conducted?
Covid explained: The trial will be conducted on 525 healthy volunteers at different sites across the country. These sites are expected to include AIIMS, Delhi and AIIMS, Patna as well as the Meditrina Institute of Medical Sciences in Nagpur.
Outlook Web Bureau
14 May 2021, Last Updated at 8:02 am
File photo
Outlook Web Bureau
2021-05-14T07:58:29+05:30
Covid Explained: How Phase 2 And 3 Trials For Covaxin On Kids Will Be Conducted?
outlookindia.com
2021-05-14T08:02:02+05:30
Also read
What is Covaxin?
Covaxin is one of the two Covid-19 vaccines used in India’s mass vaccination drive against the virus. It has been developed by Hyderabad-headquartered vaccine-maker Bharat Biotech in collaboration with the government’s Indian Council of Medical Research (ICMR). ....

Indian Council Of Medical Research , Meditrina Institute Of Medical Sciences , Expert Committee On , Bharat Biotech , Indian Council , Medical Research , Drugs Controller General , Subject Expert Committee , Meditrina Institute , Medical Sciences , இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சி , மேதிற்றின நிறுவனம் ஆஃப் மருத்துவ அறிவியல் , நிபுணர் குழு ஆன் , பாரத் பயோடெக் , இந்தியன் சபை , மருத்துவ ஆராய்ச்சி , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , பொருள் நிபுணர் குழு , மேதிற்றின நிறுவனம் , மருத்துவ அறிவியல் ,